Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anisindione is a synthetic anticoagulant and an indanedione derivative, primarily used for the prevention and treatment of venous thrombosis and its extension, atrial fibrillation with embolization, pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Its mechanism of action involves inhibition of vitamin K–mediated gamma-carboxylation of precursor proteins in the liver. This prevents the formation of active procoagulation factors II, VII, IX, and X as well as anticoagulant proteins C and S. Anisindione does not dissolve existing clots but may limit their extension or prevent secondary thromboembolic complications. It is typically prescribed only if coumarin-type anticoagulants (such as warfarin) cannot be used due to its potent effects and risk profile[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anisindione.